Cliff Bentz bought Amgen Inc (NASDAQ: AMGN)
Cliff Bentz (R-OR), a U.S. Representative, has disclosed 1 trade in Amgen Inc (AMGN) since 2025, a single purchase, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Cliff Bentz bought $1,001 - $15,000 of Amgen Inc (NASDAQ: AMGN) on June 6, 2025. Since that trade, AMGN is up +26.02% against the S&P 500 up +25.22%, an outperformance of +0.80%.
Data updated
Cliff Bentz's AMGN trades vs the price
AMGN is up +26.02% since Cliff Bentz bought on June 6, 2025, versus +25.22% for the S&P 500.
Performance since this trade
All Cliff Bentz AMGN trades
Cliff Bentz & AMGN trading FAQ
Is it legal for Cliff Bentz to trade Amgen Inc (AMGN) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Amgen Inc (AMGN), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. BullishWhales tracks those disclosures; this page does not imply the trade was improper.
When did Cliff Bentz buy AMGN?
Cliff Bentz disclosed a purchase of $1,001 - $15,000 of Amgen Inc (AMGN) on June 6, 2025, according to public STOCK Act filings.
How has AMGN performed since Cliff Bentz's trade?
Since Cliff Bentz bought AMGN on June 6, 2025, the stock is up +26.02%, versus +25.22% for the S&P 500 over the same period, an outperformance of +0.80%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional AMGN trades?
BullishWhales tracks every disclosed congressional trade in Amgen Inc (AMGN) on the Amgen Inc congressional trading page, which aggregates filings across all members of Congress.
Cliff Bentz's AMGN tradesAll congressional filings for Amgen IncCliff Bentz's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.